The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation

Acta Pharmacologica Sinica

Volumn 30, Issue 10, 2009, Pages 1443-1453

  Li, Li ^a   Wang, Xu ^b   Chen, Jing ^b   Ding, Hong ^b   Zhang, Yu ^b   Hu, Tian Cen ^b   Hu, Li Hong ^b   Jiang, Hua Liang ^a,b   Shen, Xu ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antitumor drugs; Aristolactam AIIIa; Polo box domain; Polo like kinase 1 inhibitor

Indexed keywords

ARISTOLACTAM AIIIA; ARISTOLOLACTAM; POLO LIKE KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HELA CELLS; HT29 CELLS; HUMANS; INDOLE ALKALOIDS; INHIBITORY CONCENTRATION 50; LACTAMS; LEUKEMIA L1210; LIGANDS; LUNG NEOPLASMS; MICE; MITOTIC SPINDLE APPARATUS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; STOMACH NEOPLASMS; SURFACE PLASMON RESONANCE; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 70350678893     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.141     Document Type: Article

References (33)

1. Glover DM, Hagan IM, Tavares AA. Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12: 3777-3787
2. Hamanaka R, Maloid S, Smith MR, O'Connell CD, Longo DL, Ferris DK. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994; 5: 249-257
3. Simmons DL, Neel BG, Stevens R, Evett G, Erikson RL. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol 1992; 12: 4164-4169
4. Donohue PJ, Alberts GF, Guo Y, Winkles JA. Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase. J Biol Chem 1995; 270: 10351-10357
5. Ouyang B, Pan H, Lu L, Li J, Stambrook P, Li B, et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J Biol Chem 1997; 272: 28646-28651
6. Fode C, Motro B, Yousefi S, Heffernan M, Dennis JW. Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc Natl Acad Sci USA 1994; 91: 6388-6392
7. Roshak AK, Capper EA, Imburgia C, Fornwald J, Scott G, Marshall LA. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 2000; 12: 405-411
8. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135: 1701-1713
9. Sumara I, Vorlaufer E, Stukenberg PT, Kelm O, Redemann N, Nigg EA, et al. The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Mol Cell 2002; 9: 515-525
10. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, et al. PKA and MPF-activated polo-like kinase regulate anaphasepromoting complex activity and mitosis progression. Mol Cell 1998; 1: 371-380
11. Zhou T, Aumais JP, Liu X, Yu-Lee LY, Erikson RL. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003; 5: 127-138
12. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330
13. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405.
14. Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002; 21: 3162-3171
15. Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003; 22: 69-80.
16. Jang YJ, Lin CY, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci USA 2002; 99: 1984-1989
17. Elia AE, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003; 115: 83-95.
18. Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther 2002; 303: 858-866
19. Stevenson CS, Capper EA, Roshak AK, Marquez B, Grace K, Gerwick WH, et al. Scytonemin - a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases. Inflamm Res 2002; 51: 112-114
20. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 275-286
21. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. Inhibition of pololike kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008; 15: 459-466
22. Priestap HA. Seven aristololactams from Aristolochia Argentina. Phytochemistry 1985; 24: 849-852
23. Couture A, Deniau E, Grandclaudon P, Rybalko-Rosen H, Léonce S, Pfeiffer B, et al. Synthesis and biological evaluation of Aristolactams. Bioorg Med Chem Lett 2002; 12: 3557-3559
24. Kumar V, Poonam, Prasad AK, Parmar VS. Naturally occurring Aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat Prod Rep 2003; 20: 565-583
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112
26. Diaz-Camino C, Risseeuw EP, Liu E, Crosby WL. A high-throughput system for two-hybrid screening based on growth curve analysis in microtiter plates. Anal Biochem 2003; 316; 171-174
27. Chia YC, Chang FR, Teng CM, Wu YC. Aristolactams and dioxoaporphines from Fissistigma balansae and Fissistigma oldhamii. J Nat Prod 2000; 63: 1160-1163
28. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative pololike kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11: 615-623
29. Sumara I, Giménez-Abián JF, Gerlich D, Hirota T, Kraft C, de la Torre C, et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004; 14: 1712-1722
30. Soldani C, Scovassi AI. Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002; 7: 321-328
31. Liu X, Erikson RL. Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794
32. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322
33. Lee KS, Grenfell TZ, Yarm FR, Erikson RL. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci USA 1998; 95: 9301-9306